The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Therapeutic Use
- 28 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 28 Feb 2018 Planned End Date changed from 1 Jul 2021 to 1 Oct 2017.
- 28 Feb 2018 Planned primary completion date changed from 1 Jul 2021 to 1 Oct 2017.